Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance
Rhea-AI Summary
Carlsmed (Nasdaq: CARL) reported Q3 2025 revenue of $13.1M, a 98% year‑over‑year increase, gross margin of 75.9%, and cash and equivalents of $115.5M as of September 30, 2025. The company raised full‑year 2025 revenue guidance to $49.0–$50.0M (≈80%–84% growth vs. 2024) and shortened aprevo implant lead times to 8 business days. CMS NTAP reimbursement for aprevo cervical procedures took effect Oct 1, 2025; commercial launch expected early 2026 and >50 cervical procedures completed in clinical evaluation. Carlsmed amended its debt facility to increase availability to $50M and extended maturity and interest‑only period.
Positive
- Q3 revenue of $13.1M (+98% YoY)
- Raised 2025 revenue guidance to $49.0–$50.0M (80%–84% growth)
- Gross margin at 75.9% in Q3 2025
- Reduced aprevo lead time to 8 business days beginning October
- CMS NTAP for aprevo cervical effective Oct 1, 2025 and >50 procedures
Negative
- Operating expenses increased to $19.0M in Q3 (from $12.6M)
- Net loss widened to $8.5M in Q3 2025
- Adjusted EBITDA loss of $8.2M in Q3 2025
News Market Reaction
On the day this news was published, CARL declined 1.74%, reflecting a mild negative market reaction. Argus tracked a peak move of +7.7% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $7M from the company's valuation, bringing the market cap to $371M at that time.
Data tracked by StockTitan Argus on the day of publication.
Third quarter revenue of
Raising full year 2025 revenue guidance to
CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30, 2025.
"We delivered another strong quarter with
Recent Business Highlights
- Reduced lead time for our aprevo® interbody implants to hospitals to within eight business days of surgical plan approval beginning October (from 10 business days exiting Q2 2025 and 20 business days in Q3 2024)
- CMS New Technology Add-On Payment (NTAP) went into effect on October 1, 2025, for aprevo® cervical procedures; commercial launch is expected in early 2026. To date, over 50 cervical aprevo procedures have been successfully completed by more than a dozen spine surgeons as part of our clinical evaluation program
- Data presented at the Scoliosis Research Society Annual Meeting in September demonstrated a
75% reduction in revision surgery at a two-year time point for aprevo® versus a patient matched cohort - Executed an amendment in October to our existing debt facility, increasing maximum availability to
$50 million and extending the maturity date and interest-only payment period - Announced the appointment of Jennifer Kamocsay as Chief Legal Officer and Secretary. Ms. Kamocsay brings more than a decade of corporate legal experience as counsel across the life science and technology sectors
Third Quarter 2025 Financial Results
- Revenue was
$13.1 million for the third quarter of 2025; a98% increase compared to$6.6 million for the third quarter of 2024 - Gross profit for the third quarter of 2025 was
$9.9 million compared to$4.8 million for the third quarter of 2024. Gross margin was75.9% for the third quarter of 2025, compared with72.8% for the third quarter of 2024 - Operating expenses were
$19.0 million for the third quarter of 2025, compared with$12.6 million for the third quarter of 2024, which consisted of:- Research and development expenses of
$4.4 million for the third quarter of 2025, compared with$4.0 million for the third quarter of 2024 - Sales and marketing expenses of
$9.6 million for the third quarter of 2025, compared with$6.6 million for the third quarter of 2024 - General and administrative expenses of
$4.9 million for the third quarter of 2025, compared with$1.9 million for the third quarter of 2024
- Research and development expenses of
- Net loss was (
$8.5) million for the third quarter of 2025, compared to a ($7.8) million net loss for the third quarter of 2024 - Adjusted EBITDA loss was (
$8.2) million for the third quarter of 2025, compared to ($7.7) million for the third quarter of 2024 - Cash and equivalents were
$115.5 million as of September 30, 2025
2025 Full Year Financial Outlook
- Revenue for the full year 2025 is expected to be in the range of
$49.0 t o$50.0 million , representing growth of80% to84% over 2024. This compares to prior guidance of$45.5 t o$47.5 million .
Webcast & Conference Call Details
Carlsmed will host a conference call and concurrent webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the Company’s third quarter 2025 performance. To access the webcast, please use the following link, which will provide you with dial-in details: https://edge.media-server.com/mmc/p/y7ki9icwCarlsmed Third Quarter 2025 Earnings Conference Call.
Non-GAAP Financial Measures
This press release contains certain financial information that is not presented in conformity with U.S. generally accepted accounting principles (“GAAP”), including Adjusted EBITDA. The non-GAAP financial measures are provided as supplemental information to Carlsmed’s financial measures presented in this press release that are calculated and presented in accordance with GAAP.
The Company calculates Adjusted EBITDA as net income (loss), as adjusted to exclude (i) net interest expense and income, (ii) income tax expense (benefit), (iii) depreciation and amortization expense, (iv) stock-based compensation expense and (v) change in fair value of warrant liabilities.
This non-GAAP measure is presented because management believes it allows investors to view the Company’s performance in a manner similar to the method used by management to evaluate financial performance for both strategic and annual operating planning. Management believes that to properly understand short-term and long-term financial trends, it is helpful for investors to understand the impact of the items excluded from the calculation of Adjusted EBITDA, in addition to considering the Company’s GAAP financial measures. The excluded items vary in frequency and/or impact on our results of operations and management believes that the excluded items are not reflective of the Company’s ongoing core business operations and financial condition. Excluding such items allows investors and analysts to compare our operating performance to other companies in our industry and to compare the Company’s period-over-period results.
The non-GAAP financial measures used by Carlsmed may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for Carlsmed’s financial results prepared and reported in accordance with GAAP. This non-GAAP measure has limitations as an analytical tool and should not be construed as an inference that the Company’s future results will be unaffected by unusual or non-recurring items. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business. A reconciliation of Adjusted EBITDA reported in this press release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA” later in this release. Within the accompanying financial tables presented, certain columns and rows may not add due to the use of rounded numbers.
About Carlsmed
Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.
Forward Looking Statement
Any statements in this press release about future expectations, plans and prospects, including statements about the Carlsmed’s ability to scale the impact of its aprevo® technology platform and advance its personalized spine surgery platform to transform patient outcomes and drive long-term growth, Carlsmed’s current expectation of commercially launching aprevo® cervical in the United States in 2026, the number ranges presented in our 2025 Full Year Financial Outlook, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption “Risk Factors” in the Carlsmed’s Registration Statement on Form S-1 on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed’s views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed’s views as of any date subsequent to the date of this press release.
Investor Relations
Caroline Corner, PhD
Media
LeAnn Burton
Senior Director Brand Marketing
LBurton@Carlsmed.com
CARLSMED, INC.
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share amounts)
(unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue | $ | 13,074 | $ | 6,590 | $ | 35,346 | $ | 17,757 | ||||||||
| Cost of sales | 3,147 | 1,792 | 8,914 | 4,733 | ||||||||||||
| Gross profit | 9,927 | 4,798 | 26,432 | 13,024 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 4,445 | 4,035 | 11,755 | 11,289 | ||||||||||||
| Sales and marketing | 9,610 | 6,622 | 24,218 | 15,092 | ||||||||||||
| General and administrative | 4,907 | 1,918 | 11,715 | 6,068 | ||||||||||||
| Total operating expenses | 18,962 | 12,575 | 47,688 | 32,449 | ||||||||||||
| Loss from operations | (9,035) | (7,777) | (21,256) | (19,425) | ||||||||||||
| Other income (expense): | ||||||||||||||||
| Interest expense | (380) | (402) | (1,100) | (943) | ||||||||||||
| Interest income | 954 | 394 | 1,670 | 920 | ||||||||||||
| Change in fair value of warrant liabilities | (65) | (28) | (335) | (89) | ||||||||||||
| Total other income (expense), net | 509 | (36) | 235 | (112) | ||||||||||||
| Net loss and comprehensive loss | (8,526) | (7,813) | (21,021) | (19,537) | ||||||||||||
| Deemed dividend to preferred stockholders | — | (592) | (584) | (592) | ||||||||||||
| Net loss attributable to common stockholders | $ | (8,526) | $ | (8,405) | $ | (21,605) | $ | (20,129) | ||||||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.40) | $ | (2.06) | $ | (2.15) | $ | (4.97) | ||||||||
| Weighted-average number of common shares used to compute basic and diluted net loss per share | 21,081,330 | 4,088,553 | 10,051,623 | 4,046,210 | ||||||||||||
CARLSMED, INC.
CONDENSED BALANCE SHEETS
(in thousands, except for share and par value amounts)
(unaudited)
| September 30, 2025 | December 31, 2024 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 115,373 | $ | 40,125 | ||||
| Restricted cash | 100 | 100 | ||||||
| Accounts receivable, net of allowances of December 31, 2024, respectively | 11,296 | 6,766 | ||||||
| Inventory | 1,340 | 995 | ||||||
| Prepaid expenses and other current assets | 3,356 | 1,365 | ||||||
| Total current assets | 131,465 | 49,351 | ||||||
| Property and equipment, net | 1,187 | 260 | ||||||
| Operating lease right-of-use assets | 1,986 | 1,644 | ||||||
| Other assets | 225 | 569 | ||||||
| Total assets | $ | 134,863 | $ | 51,824 | ||||
| Liabilities, Convertible Preferred Stock, and Stockholders’ Equity (Deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,672 | $ | 2,412 | ||||
| Accrued liabilities | 3,186 | 2,687 | ||||||
| Accrued compensation | 4,409 | 3,270 | ||||||
| Short-term operating lease liabilities | 661 | 449 | ||||||
| Total current liabilities | 10,928 | 8,818 | ||||||
| Long-term portion of term loan, net | 15,440 | 15,414 | ||||||
| Long-term operating lease liabilities | 1,513 | 1,317 | ||||||
| Warrant liabilities | 32 | 457 | ||||||
| Other long-term liabilities | 290 | 222 | ||||||
| Total liabilities | 28,203 | 26,228 | ||||||
| Commitments and contingencies (Note 9) | ||||||||
| Series A convertible preferred stock, | — | 13,578 | ||||||
| Series B convertible preferred stock, | — | 29,801 | ||||||
| Series C convertible preferred stock, | — | 52,847 | ||||||
| Stockholders’ equity (deficit): | ||||||||
| Preferred stock, | — | — | ||||||
| Common stock, | — | — | ||||||
| Additional paid-in capital | 198,852 | 541 | ||||||
| Accumulated deficit | (92,192) | (71,171) | ||||||
| Total stockholders’ equity (deficit) | 106,660 | (70,630) | ||||||
| Total liabilities, convertible preferred stock, and stockholders’ equity (deficit) | $ | 134,863 | $ | 51,824 | ||||
RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA
(unaudited)
| Three Months Ended September 30, | $ | % | ||||||||||||||||||
| 2025 | 2024 | Change | Change | |||||||||||||||||
| (in thousands, except percentages) | ||||||||||||||||||||
| Net loss | $ | (8,526) | $ | (7,813) | $ | (713) | ||||||||||||||
| Interest (income) expense | (574) | 8 | (582) | ** | ||||||||||||||||
| Income taxes | — | — | — | — | ||||||||||||||||
| Depreciation and amortization | 82 | 33 | 49 | |||||||||||||||||
| EBITDA | (9,018) | (7,772) | (1,246) | |||||||||||||||||
| Stock-based compensation | 704 | 66 | 638 | |||||||||||||||||
| Change in fair value of warrant liabilities | 65 | 28 | 37 | |||||||||||||||||
| Adjusted EBITDA | $ | (8,249) | $ | (7,678) | $ | (571) | ||||||||||||||
| Nine Months Ended September 30, | $ | % | ||||||||||||||||||
| 2025 | 2024 | Change | Change | |||||||||||||||||
| (in thousands, except percentages) | ||||||||||||||||||||
| Net loss | $ | (21,021) | $ | (19,537) | $ | (1,484) | ||||||||||||||
| Interest (income) expense | (570) | 23 | (593) | ** | ||||||||||||||||
| Income taxes | — | — | — | — | ||||||||||||||||
| Depreciation and amortization | 183 | 108 | 75 | |||||||||||||||||
| EBITDA | (21,408) | (19,406) | (2,002) | |||||||||||||||||
| Stock-based compensation | 1,137 | 153 | 984 | |||||||||||||||||
| Change in fair value of warrant liabilities | 335 | 89 | 246 | |||||||||||||||||
| Adjusted EBITDA | $ | (19,936) | $ | (19,164) | $ | (772) | ||||||||||||||
** Change not meaningful
FAQ
What were Carlsmed (CARL) third quarter 2025 results?
How did Carlsmed change full‑year 2025 guidance on November 6, 2025?
What does the Oct 1, 2025 NTAP decision mean for CARL?
How much cash did Carlsmed hold at September 30, 2025?
Did Carlsmed change its debt facility in October 2025?
What clinical evidence did Carlsmed report regarding aprevo outcomes?
